Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Carlsmed (CARL) Gains from Investment Securities (2024 - 2025)

Carlsmed filings provide 2 years of Gains from Investment Securities readings, the most recent being $100000.0 for Q4 2025.

On a quarterly basis, Gains from Investment Securities rose 150.0% to $100000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $28000.0, a N/A change, with the full-year FY2025 number at $1.7 million, down 4.8% from a year prior.
Gains from Investment Securities hit $100000.0 in Q4 2025 for Carlsmed, down from $1.6 million in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $1.6 million in Q3 2025 to a low of -$200000.0 in Q4 2024.